## **Core Concept**
The question tests knowledge of pharmacokinetics and pharmacodynamics of muscle relaxants, particularly in the context of organ dysfunction. Muscle relaxants are drugs that interfere with muscle contraction, and their choice in patients with renal and hepatic failure requires careful consideration of their metabolism and excretion.

## **Why the Correct Answer is Right**
Atracurium is the correct answer because it is metabolized by **Hoffmann elimination**, a non-enzymatic degradation process that occurs in plasma and is independent of liver and kidney function. This unique property makes atracurium an ideal choice for patients with both renal and hepatic failure, as its elimination is not significantly affected by the function of these organs.

## **Why Each Wrong Option is Incorrect**
* **Option A:** Succinylcholine is metabolized rapidly by plasma cholinesterase, and its duration of action is not significantly affected by renal or hepatic failure. However, it is not typically used for prolonged muscle relaxation and has side effects that limit its use.
* **Option B:** Vecuronium is primarily metabolized by the liver and excreted in bile, with some metabolites excreted by the kidneys. Its use in hepatic failure may require dose adjustment.
* **Option D:** Pancuronium is primarily excreted unchanged by the kidneys, making it a less favorable choice in renal failure.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that atracurium's metabolite, laudanosine, has potential central nervous system effects, but this does not detract from its utility in patients with combined organ failure. Atracurium is often considered a safe option in such scenarios.

## **Correct Answer:** . Atracurium